5017 Multinational study (n = 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391 Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Cortes-Funes, H
  • Pritchard, Kathleen
  • Biganzoli, L
  • Thomssen, C
  • Pierga, J
  • Koza, I
  • Kwong, A
  • Kellokumpu-Lehtinen, P
  • Chlistalla, A
  • Smith, I

publication date

  • September 2009